bilaterals.org logo
bilaterals.org logo

medicines


India, US trade deal: New Delhi seeks preferential treatment on drugs, other goods
India is seeking concessions for generic drugs it exports to the United States in return for opening its dairy markets and slashing tariffs on farm goods as the two sides seek to shore up a new trade deal.
Union calls for equal recognition for healthcare workers
The union and its allies also asked the government not to join the Trans-Pacific Partnership, as they view that the restriction of rights to access medicine under the deal would put the country’s public health system in danger.
If the government doesn’t halt trade talks with Trump, it’s learned nothing from coronavirus
The US trade model is not only unpopular with the British public, but it will also make us more vulnerable to future pandemics.
Covid-19: Why India doesn’t need to worry about investor-State dispute settlement claims
In order to halt the spread of the coronavirus pandemic (Covid-19) and to boost the public health care system and preparedness, India has taken several regulatory steps.
The Comprehensive and Progressive Agreement for the Trans-Pacific Partnership: Data exclusivity and access to biologics
The agreement does not promise that the suspended provision on test data rule concerning biological medicines will remain suspended.
Intellectual property rights: Potential implications of the DCFTA for access to medicine
If the intellectual property provisions of the DCFTA are applied, this will have an impact on both the cost of patented medicines and undermine access to affordable medicines.
Can a US-India trade deal permanently alter the way Indians access medicines?
US-India IP engagements since 2006 have served the interests of the US through systematic undermining of the legislative safeguards in the Indian Patents Act.
Trump will insist NHS pays more for drugs in trade deal, says ambassador
Donald Trump will put the interests of corporate America first and demand that the NHS pays higher prices for US drugs in a free-trade deal with the UK, the outgoing British ambassador to Washington said.
Phase 1 US China trade deal: patent provisions
China agreed to extend patent terms for novel drugs "to compensate for unreasonable delays that occur in granting the patent or during pharmaceutical product marketing approvals."
India, Indonesia negotiating economic cooperation agreement
India and Indonesia are set to launch negotiations for a Comprehensive Economic Cooperation Agreement (CECA) to cover economic cooperation while trading in goods, services, and investments.
Blueprint for a human rights impact assessment of the planned comprehensive free trade agreement between EFTA and Mercosur
This study assesses the impact of the EFTA-Mercosur free trade agreement on access to medicines, indigenous rights and women rights.
Mexico sees progress in talks to revise USMCA, says drug protections to ease
Mexico’s government said progress was being made toward revising a new North American trade pact that will sharply reduce protections for biologic drugs.
Trump administration considers loosening drug protections in USMCA
Generic versions of biologic drugs could come to market faster.
How to protect the NHS in a post-Brexit trade deal with the US
There are two solutions to this impending problem, which most political parties could agree to if they are truly committed to protecting the NHS.
New AFTINET fact sheet: The impact of trade and investment rules on public health
Trading away our health: How trade and investment rules put corporate rights ahead of public health.
As Modi visits US, what does the free trade pact mean for India’s pharma industry?
A Free Trade Agreement with the US will likely result in the amendment of the Patents Act, which could impact the Indian pharma industry.
US farmers’ group says pharma, not dairy, is main obstacle to ratifying USMCA
The National Farmers Union says the new deal’s extended patent protection for new pharmaceuticals must be reduced so that less expensive generic versions of new drugs can be available to consumers sooner.
EU-US trade talks: milestone reached in mutual recognition on pharmaceuticals
The mutual recognition agreement for inspections of manufacturing sites for human medicines in their respective territories can make it faster and less costly for both sides to bring medicines to the market.
Old wine in new bottles: Keep TRIPS-plus provisions out of the RCEP FTA!
Intellectual property barriers, which would hinder access to affordable medicines, have supposedly been removed from the draft RCEP free-trade agreement (FTA).
India protects drug, agriculture business at RCEP
Three harmful provisions concerning pharmaceuticals and agriculture which were part of the RCEP have been withdrawn.